384 related articles for article (PubMed ID: 30835007)
1. Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
Chua J; Nafziger E; Leung D
Curr Oncol Rep; 2019 Mar; 21(4):30. PubMed ID: 30835007
[TBL] [Abstract][Full Text] [Related]
2. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
Koukourakis GV; Kouloulias V; Zacharias G; Papadimitriou C; Pantelakos P; Maravelis G; Fotineas A; Beli I; Chaldeopoulos D; Kouvaris J
Molecules; 2009 Apr; 14(4):1561-77. PubMed ID: 19384285
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
[TBL] [Abstract][Full Text] [Related]
4. [Prescription guidebook for temozolomide usage in brain tumors].
Tilleul P; Brignone M; Hassani Y; Taillandier L; Taillibert S; Cartalat-Carel S; Borget I; Chinot O
Bull Cancer; 2009 May; 96(5):579-89. PubMed ID: 19467988
[TBL] [Abstract][Full Text] [Related]
5. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
[TBL] [Abstract][Full Text] [Related]
6. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
Sipos L; Vitanovics D; Afra D
Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
[TBL] [Abstract][Full Text] [Related]
7. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
8. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
[TBL] [Abstract][Full Text] [Related]
10. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
[TBL] [Abstract][Full Text] [Related]
11. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
Parlato C; Barbarisi M; Moraci M; Moraci A
Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
[TBL] [Abstract][Full Text] [Related]
12. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
[TBL] [Abstract][Full Text] [Related]
14. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
[TBL] [Abstract][Full Text] [Related]
15. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
Schiff D
Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
Rosenthal MA; Ashley DL; Cher L
Intern Med J; 2002 Jul; 32(7):346-8. PubMed ID: 12088355
[TBL] [Abstract][Full Text] [Related]
18. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
[TBL] [Abstract][Full Text] [Related]
19. Temozolomide for immunomodulation in the treatment of glioblastoma.
Karachi A; Dastmalchi F; Mitchell DA; Rahman M
Neuro Oncol; 2018 Nov; 20(12):1566-1572. PubMed ID: 29733389
[TBL] [Abstract][Full Text] [Related]
20. MGMT promoter hypermethylation correlates with a survival benefit from temozolomide in patients with recurrent anaplastic astrocytoma but not glioblastoma.
Sadones J; Michotte A; Veld P; Chaskis C; Sciot R; Menten J; Joossens EJ; Strauven T; D'Hondt LA; Sartenaer D; Califice SF; Bierau K; Svensson C; De Grève J; Neyns B
Eur J Cancer; 2009 Jan; 45(1):146-53. PubMed ID: 18945611
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
